Early Detection Research Network
Team Project

Liver Rapid Reference Set Application: Hemken - Abbott (2015)

Liver Rapid Ref Set App: Hemken (2015)
415
Hemken, Philip MAbbott Diagnostics R&D

No coordinating investigator defined.

GP73, fucosylated hemopexin (Fuc-HPX), AFP, PIVKA-II
No design specified.
Proteomics
[u'G.I. and Other Associated Cancers Research Group']
2

The aim for this testing is to find a small panel of biomarkers (n=2-5) that can be tested on the Abbott ARCHITECT automated immunoassay platform for the early detection of hepatocellular carcinoma (HCC). This panel of biomarkers should perform significantly better than alpha-fetoprotein (AFP) alone based on multivariate statistical analysis. This testing of the EDRN reference set will help expedite the selection of a small panel of ARCHITECT biomarkers for the early detection of HCC. The panel of ARCHITECT biomarkers Abbott plans to test include: AFP, protein induced by vitamin K absence or antagonist-II (PIVKA-II), golgi protein 73 (GP73), hepatocellular growth factor (HGF), dipeptidyl peptidase 4 (DPP4) and DPP4/seprase (surface expressed protease) heterodimer hybrid. PIVKA-II is abnormal des-carboxylated prothrombin (DCP) present in vitamin K deficiency.

The aim for this testing is to find a small panel of biomarkers (n=2-5) that can be tested on the Abbott ARCHITECT automated immunoassay platform for the early detection of hepatocellular carcinoma (HCC). This panel of biomarkers should perform significantly better than alpha-fetoprotein (AFP) alone based on multivariate statistical analysis. This testing of the EDRN reference set will help expedite the selection of a small panel of ARCHITECT biomarkers for the early detection of HCC. The panel of ARCHITECT biomarkers Abbott plans to test include: AFP, protein induced by vitamin K absence or antagonist-II (PIVKA-II), golgi protein 73 (GP73), hepatocellular growth factor (HGF), dipeptidyl peptidase 4 (DPP4) and DPP4/seprase (surface expressed protease) heterodimer hybrid. PIVKA-II is abnormal des-carboxylated prothrombin (DCP) present in vitamin K deficiency.
The goal of this testing is to find a panel of biomarkers that significantly perform better than AFP alone for the early detection of HCC. The data analysis plan will reflect this goal by analyzing the data in univariate and multivariate manner using the statistical software JMP version 11 to generate dot plots and AUCs. Verification of data analysis will be performed by Abbott statisticians for both univariate and multivariate analysis. In parallel, statisticians from EDRN will analyze the data to see if both Abbott and EDRN analyses agree. Abbott will need to know the specimen key for this analysis in order to generate dot plots and AUCs. V. Future Plans If a small panel of ARCHITECT biomarkers shows promising performance, Abbott is definitely interested

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.